Creating a Global Company

Financials Market Capitalisation Rs. 2,100 billion / US$ 29 billion (as of 17th March 2022) FY17 YOY FY18 ** YOY FY19 YOY FY20 YoY SUN PHARMA (All Figures in Rs. Mn) FY21 YoY P&L Summary Sales 302,642 Gross Profit 221,335 3% 9% 260,659 186,413 EBITDA 87,751 16% 51,846 Net Profit 69,644 53% 20,957 -14% 286,863 -16% 208,173 -41% 59,280 -70% 26,654 10% 323,252 12% 230,947 13% 332.331 3% 11% 245,430 6% 14% 64,774 9% 82,263 27% 27% 37,649 41% 29,038 -23% Net Profit (Adjusted) 69,644 33% 33,006# -53% 38,798 18% 40,256# 4% 59,317 # 47% R&D Spend 23,138 0% 22,489 -3% 19.847 -12% 19,739 -1% 21,499 9% BS Summary Mar'17 YOY Mar'18 YoY Mar'19 YOY Mar'20 Shareholders Funds 366,397 11% 383,141 5% 414,091 8% 452,645 Loan Funds 80,910 Net Fixed Assets 149,404 -3% 20% 157,110 97,518 21% 98,934 1% 75,783 YOY Mar'21 9% 464,628 -23% 33,430 YOY 3% -56% 5% 172,919 Investments 11.919 -35% 71,430 499% 79,030 10% 175,858 11% 101,431 2% 168,322 -4% 28% 96,125 -5% Cash and Bank Balances 151,408 15% 99,290 -34% 72,760 -27% 64,876 -11% 64,455 -1% Inventory 68,328 6% 68,810 1% 78,860 15% 78,750 0% 89,970 14% Sundry Debtors 72,026 6% 78,150 9% 88,840 14% 94,212 6% 90,614 -4% Sundry Creditors 43,954 23% 47,660 8% 41,480 -13% 35,836 -14% 39,737 11% # FY18 - Adjusted for Rs. 12.1 bn provision related to Modafinil settlement & deferred tax adjustment # FY19 - Adjusted for Rs. 12 bn provision related to Modafinil settlement **FY19 - Includes a one-time sales reduction of Rs. 10,850mn related to change in distribution for India business # FY20 - Adjusted for Rs. 2.6 bn provision (related to Dusa US DoJ settlement of Rs. 1.6 bn and Indirect Tax provision of Rs. 1.0 bn in India) # FY21 - Adjusted for Rs. 30.3 bn provision (related to Taro US - DOJ & MDL settlement Rs. 42.2, Rs. 0.9 bn provision related to UK Citalopram case, Rs. 4.1 bn related to deferred tax gain. Taro provisions are adjusted for minority interest) 45

View entire presentation